Detalhe da pesquisa
1.
Lenalidomide-based triplet regimens in first relapsed multiple myeloma patients: real-world evidence from a propensity score matched analysis.
Haematologica
; 108(3): 833-842, 2023 03 01.
Artigo
Inglês
| MEDLINE | ID: mdl-36200419
2.
A prospective, multicenter study on hematopoietic stem-cell mobilization with cyclophosphamide plus granulocyte colony-stimulating factor and 'on-demand' plerixafor in multiple myeloma patients treated with novel agents.
Haematologica
; 2023 Nov 16.
Artigo
Inglês
| MEDLINE | ID: mdl-37981892
3.
Cross-Dressing of Multiple Myeloma Cells Mediated by Extracellular Vesicles Conveying MIC and ULBP Ligands Promotes NK Cell Killing.
Int J Mol Sci
; 24(11)2023 May 30.
Artigo
Inglês
| MEDLINE | ID: mdl-37298418
4.
Autologous stem cell transplantation in multiple myeloma patients over 70 years: A GIMEMA Lazio Working Group experience in a retrospective case-control study.
Eur J Haematol
; 109(3): 250-256, 2022 Sep.
Artigo
Inglês
| MEDLINE | ID: mdl-35617025
5.
Venous thromboembolism prophylaxis in patients with multiple myeloma: where are we and where are we going?
J Thromb Thrombolysis
; 52(2): 584-589, 2021 Aug.
Artigo
Inglês
| MEDLINE | ID: mdl-33417149
6.
High rate of profound clonal and renal responses with daratumumab treatment in heavily pre-treated patients with light chain (AL) amyloidosis and high bone marrow plasma cell infiltrate.
Am J Hematol
; 95(8): 900-905, 2020 08.
Artigo
Inglês
| MEDLINE | ID: mdl-32282971
7.
Single-molecule real-time sequencing of the M protein: Toward personalized medicine in monoclonal gammopathies.
Am J Hematol
; 97(11): E389-E392, 2022 11.
Artigo
Inglês
| MEDLINE | ID: mdl-35997169
8.
Severe SARS-CoV-2 and subsequent fungal infections after CAR T-cell therapy for relapsed/refractory multiple myeloma: a challenging and happy ending fight.
Leuk Res Rep
; 21: 100399, 2024.
Artigo
Inglês
| MEDLINE | ID: mdl-38078287
9.
CD38 restrains the activity of extracellular cGAMP in a model of multiple myeloma.
iScience
; 27(5): 109814, 2024 May 17.
Artigo
Inglês
| MEDLINE | ID: mdl-38746669
10.
Belantamab Mafodotin: From Clinical Trials Data to Real-Life Experiences.
Cancers (Basel)
; 15(11)2023 May 27.
Artigo
Inglês
| MEDLINE | ID: mdl-37296910
11.
Sialofucosylation Enables Platelet Binding to Myeloma Cells via P-Selectin and Suppresses NK Cell-Mediated Cytotoxicity.
Cancers (Basel)
; 15(7)2023 Apr 05.
Artigo
Inglês
| MEDLINE | ID: mdl-37046814
12.
Multiparametric Flow Cytometry in Newly Diagnosed Multiple Myeloma Patients: An Italian Monocentric Experience.
Mediterr J Hematol Infect Dis
; 15(1): e2023047, 2023.
Artigo
Inglês
| MEDLINE | ID: mdl-37705525
13.
NEDD8-activating enzyme inhibition potentiates the anti-myeloma activity of natural killer cells.
Cell Death Dis
; 14(7): 438, 2023 07 17.
Artigo
Inglês
| MEDLINE | ID: mdl-37460534
14.
Race for the Cure: From the Oldest to the Newest Monoclonal Antibodies for Multiple Myeloma Treatment.
Biomolecules
; 12(8)2022 08 19.
Artigo
Inglês
| MEDLINE | ID: mdl-36009041
15.
GAS6/TAM signaling pathway controls MICA expression in multiple myeloma cells.
Front Immunol
; 13: 942640, 2022.
Artigo
Inglês
| MEDLINE | ID: mdl-35967396
16.
Immunogenicity of SARS-CoV-2 vaccination in patients undergoing autologous stem cell transplantation. A multicentric experience.
Front Oncol
; 12: 897937, 2022.
Artigo
Inglês
| MEDLINE | ID: mdl-36531008
17.
Impact on NK cell functions of acute versus chronic exposure to extracellular vesicle-associated MICA: Dual role in cancer immunosurveillance.
J Extracell Vesicles
; 11(1): e12176, 2022 01.
Artigo
Inglês
| MEDLINE | ID: mdl-34973063
18.
Daratumumab combined with dexamethasone and lenalidomide or bortezomib in relapsed/refractory multiple myeloma (RRMM) patients: Report from the multiple myeloma GIMEMA Lazio group.
EJHaem
; 3(1): 121-128, 2022 Feb.
Artigo
Inglês
| MEDLINE | ID: mdl-35846211
19.
An N-glycosylation hotspot in immunoglobulin κ light chains is associated with AL amyloidosis.
Leukemia
; 36(8): 2076-2085, 2022 08.
Artigo
Inglês
| MEDLINE | ID: mdl-35610346
20.
High Levels of Circulating Tumor Plasma Cells as a Key Hallmark of Aggressive Disease in Transplant-Eligible Patients With Newly Diagnosed Multiple Myeloma.
J Clin Oncol
; 40(27): 3120-3131, 2022 09 20.
Artigo
Inglês
| MEDLINE | ID: mdl-35666982